Genome-wide qPCR with increased primer multiplexity for diagnostics and drug screening
This technology is a qPCR method that increases the number of genes measured per experiment, enabling highly multiplexed gene expression testing for drug screening and biomedical diagnostics.
Unmet Need: Fast, cost-effective multiplexed method for analyzing gene expression
Quantitative polymerase chain reaction (qPCR) is the most common method for measuring gene expression. Current qPCR technologies are limited to measuring a few genes per experiment. For studies with a narrow scope, where only a few targets are of interest, these methods are sufficient. However, for the characterization of the human genome and human disease states, there remains a need for cost- and time-efficient gene expression analysis methods that can simultaneously run 100-1000 genetic targets.
The Technology: qPCR method for increasing the number of genes measured per experiment
This technology is a qPCR method that utilizes bioengineered, unique gene primer microbeads and Raman spectroscopy to measure gene expression in a biological sample. The combination of small molecules on the microbeads generates a distinct optical barcode, enabling increased qPCR multiplexity by several orders of magnitude. The ability to measure more genes per experiment decreases turnaround time for gene analysis results and lowers the cost per gene target, making this technology ideal for characterizing the human genome or analyzing human disease states that require the analysis of many gene targets.
Applications:
- Pathogen diagnostics and surveillance
- Diagnostics for precision medicine approaches
- Drug screening
- Research tool for gene expression analyses and nucleic acid detection
- CRISPR screening
- Genetics-based prognostics
Advantages:
- Increased number of gene targets per qPCR run
- Broader genome characterization
- Cost-effective
- Lower turnaround time for broad gene expression analysis
Lead Inventor:
Patent Information:
Patent Pending
Related Publications:
Tech Ventures Reference:
IR CU23284, CU22302
Licensing Contact: Dovina Qu